Genome Canada

AmorChem’s RNA Zipcode Delivery Technology Investment Exits via New York-Based Kodikaz Therapeutic Solutions, Inc.

Retrieved on: 
Tuesday, May 21, 2024
Oncology, Health, Health Technology, General Health, Research, Science, Biotechnology, Patient, General partnership, Intelligence, McGill University, CSO, RNA, Therapy, Genome Canada, Innovation, Vaccine

AmorChem II Fund L.P. (''AmorChem'') is delighted to announce that its RNA Zipcode delivery program has been acquired by Kodikaz Therapeutic Solutions, Inc. (''Kodikaz''), a New York City biotech focused on targeted delivery of cancer therapeutics.

Key Points: 
  • AmorChem II Fund L.P. (''AmorChem'') is delighted to announce that its RNA Zipcode delivery program has been acquired by Kodikaz Therapeutic Solutions, Inc. (''Kodikaz''), a New York City biotech focused on targeted delivery of cancer therapeutics.
  • The RNA Zipcode program was the first university-based investment of AmorChem’s second fund and was developed by Professors Eric Lécuyer (Montreal Clinical Research Institute), Mathieu Blanchette (McGill University), and Jérôme Waldispühl (McGill University).
  • ''The success of our RNA Zipcode program highlights our specialized investment strategy: digging deep into Quebec academia searching for novel therapeutic approaches that will benefit patients.
  • ''This is a great opportunity to partner with world-renowned inventors that bring expertise in artificial intelligence and RNA delivery.

Using genomics to reduce the carbon footprint of the agri-food industry

Retrieved on: 
Wednesday, September 6, 2023
Genome Canada, Genomics, Fertilizer, Fishery, Parafilm, Centrale, Fungus, Science, Forestry, Transport, INRS, David Suzuki Foundation, Waste management, Ivey Business School, Research, Government, Tricycle, Compost, McGill University, Local government in Canada, Université de Montréal, Bacteria, Treasury Board of Canada, Environment and Climate Change Canada, LOOP, DNA, Biotron (Western University), Climate change, Carbon, Montreal Botanical Garden, The Wilderness Society, Climate change mitigation, Environment, Greenhouse, Food, Western University, Agriculture, University, Park, City, Food chain, CO2, Farm, Cryptocurrency, Management, Landfill, Renewable energy, Municipality of the County of Inverness

With that in mind, new approaches are essential to reduce the carbon footprint of the country's agri-food sector.

Key Points: 
  • With that in mind, new approaches are essential to reduce the carbon footprint of the country's agri-food sector.
  • In other words, how are agri-food byproducts or food leftovers biodegraded by microorganisms, fungi or insects that feed on them?
  • Their expertise will help us reduce the carbon footprint of Canada's food production systems while continuing to develop innovation."
  • As a result of their work, the research teams will propose biotechnological innovations to reduce the carbon footprint of Canada's bio-food production systems.

Aptum Strengthens Leadership Team with Key Appointments to Drive AI-Driven Multi-Cloud Market Growth

Retrieved on: 
Tuesday, August 22, 2023
Technology, Security, Consulting, Other Technology, Professional Services, Software, Networks, Data Management, Artificial Intelligence, Other Professional Services, Cloud, Genome Canada, VMware, Senior, Consultant, Air Transat, OVH, Cloud computing, Advisory, Acquisition, Commvault, DigitalBridge, Investment, Engineering, Managed services, Dell EMC, Rosato, Management, Software as a service, Panzura, Aptum Technologies

These strategic additions to the executive team are integral to Aptum’s vision to capitalize on the growing AI-driven demand of Multi-Cloud solutions in the market.

Key Points: 
  • These strategic additions to the executive team are integral to Aptum’s vision to capitalize on the growing AI-driven demand of Multi-Cloud solutions in the market.
  • Ian Rae assumes the role of CEO and President effective September 1, 2023, following Aptum’s successful acquisition of CloudOps in January 2023.
  • A seasoned entrepreneur and technology visionary, Rae founded CloudOps in 2005, as well as cloud.ca, a leading Canadian cloud computing platform.
  • With his extensive expertise in cloud operations, software development, and managed services, Rae brings invaluable insights to his new leadership role.

Asep Inc. Receives Grant from NanoMedicines Innovation Network (NMIN), Funded by the Government of Canada

Retrieved on: 
Saturday, June 24, 2023
Genome Canada, Network, ASEP, Human, CSE, University, Bill & Melinda Gates Foundation, CAD, FSE, Federal, USD, Government, Organization, United States Army, NEPAD African Western and Southern Networks of Centres of Excellence in Water Sciences, United States Department of the Army, Investigational New Drug, NCE, Toxicology, Local government in Canada, FDA, UBC, Biofilm, Pharmacology, Peptide, Pharmaceutical industry

The Government of Canada funds NMIN through the Networks of Centres of Excellence (NCE) Program.

Key Points: 
  • The Government of Canada funds NMIN through the Networks of Centres of Excellence (NCE) Program.
  • To date, the Company and its subsidiaries have received over USD $20 million in non-dilutive grant funding from organizations such as the Bill and Melinda Gates Foundation, Genome Canada and UBC.
  • The Company, through its pre-clinical partner, iFyber LLC, has also received funding from the US Army for its novel antibiofilm peptide technology.
  • The grant title is "Pre-clinical evaluation of nanoparticle formulations for the in vivo delivery of anti-biofilm and anti-inflammatory synthetic host defence peptides."

Global Genome Editing Market Report 2023: Players Include Sangamo Therapeutics, Precision Biosciences, Cellectis, Merck and Lonza - ResearchAndMarkets.com

Retrieved on: 
Friday, June 16, 2023
Health, Genetics, Genome Canada, Vaccine, CRISPR, DNA, ZFN, Biotechnology, Prevalence, Agriculture, COVID-19, MEA, Research, Medicine, Genomics, Genome, USD, Cas9, Forecasting, Government, Ministry, Incidence, Investment, Engineering, Plant growth analysis, Delivery, Mode, Growth, TALEN, Environment, Gene, Disease, Antibiotics, Fine chemical, Science, Application

As a result, the Genome Editing Market will increase favourably during the period of forecasting.

Key Points: 
  • As a result, the Genome Editing Market will increase favourably during the period of forecasting.
  • Recently, the market has grown primarily due to the expanding usage of CRISPR genome editing technology and increased demand for synthetic genes in various biotechnology fields.
  • The Global Genome Editing Market is segmented based on Technology, Delivery Method, Mode, End-use, Application, and Region.
  • Genome editing and engineering technologies have gained prominence because to the rising demand for vaccines and antiviral candidates; these reasons are anticipated to propel the genome editing market in the years to come.

Oral Clinical Nutrition Market Size, Share & Trends Analysis Report By Stage, By Indication, By Sales Channel, By Region And Segment Forecasts, 2023 - 2030

Retrieved on: 
Tuesday, March 14, 2023
Nutrient deficiency, Protein, Conditional sentence, Alzheimer's disease, Government, Electrolyte, Genome Canada, Somatic symptom disorder, Incidence, Clinical, R, Prevalence, Immunity, Hypertension, Ottawa University, White House conference, Vitamin, Cancer, Filament, Abbott, Growth, COVID-19, Dicarboxylic acid, CIHR, Research, CHEO, Sale, Obesity, Oral, Dysphagia, Mineral, Conference, Malnutrition, Food, Vitamin D, IBD, USD, Yogurt, Dietary supplement, Hospital, Pediatrics, Health, Hunger

They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.

Key Points: 
  • They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.
  • Such initiative has led to the development of more advanced and effective oral clinical nutrition supplements, which has increased their adoption and growth in the market.
  • Further, the COVID-19 pandemic has had a positive impact on the oral clinical nutrition market.The demand for oral clinical nutrition supplements has increased catering to the issues faced due to malnutrition.
  • Cancer care segment held the largest share in 2022 owing to its rising prevalence and hospital admissions for cancer treatment.

Government of Canada releases results of public consultations on the future of genomics in Canada

Retrieved on: 
Monday, March 13, 2023
Government, Innovation, Science and Economic Development Canada, Research, Natural Resources, Agriculture, Forestry, Environment, Canadian Food Inspection Agency, Climate change, Investment, Health, Genome Canada, Public Health Agency of Canada, Agriculture and Agri-Food Canada, Economic development, Fishery, National Human Genome Research Institute, Natural Resources Canada, National Research Council Canada, Mining, Food, Report, Public, Government of Canada, COVID-19, The Honourable, Public Health Agency, Antibiotics, Genomics, Science, Innovation

With world-class strength in genomics research, Canada has positioned itself as a global leader in genomics over the past years.

Key Points: 
  • With world-class strength in genomics research, Canada has positioned itself as a global leader in genomics over the past years.
  • It presents the results of the public consultations undertaken in spring and summer 2022 to inform the upcoming Pan-Canadian Genomics Strategy.
  • The Government of Canada will continue to collaborate closely with Canada's genomics community to develop the Pan-Canadian Genomics Strategy.
  • Genomics research requires close collaboration with many government organizations, such as Agriculture and Agri-Food Canada, the Canadian Food Inspection Agency, National Research Council Canada, Natural Resources Canada and the Public Health Agency of Canada.

CLARIFICATION - Asep Medical Holdings Inc. Provides Update on its Prior Disclosure Regarding Proprietary Diagnostic & Therapeutic Technologies

Retrieved on: 
Wednesday, December 28, 2022
Genome Canada, Overalls, Infection, Sinusitis, University, ASEP, Safety, Disease, News, Bill, IIROC, IPO, Lung, Bacteria, Toxicity, Patient, Biofilm, Risk, FDA, Inflammation, FSE, Survival, Skin, Mortality, Patent, Diagnosis, Sepsis, Peer review, Pharmacokinetics, Hospital, Volunteering, Organization, Death, Disclosure, CSE, Medicine, Probability, Throat, Bill & Melinda Gates Foundation, Physician, Vaccine, Medical device, Pharmaceutical industry, Fine chemical, UBC

The diagnostic test, developed under the direction of leading UBC microbiologist and the Company's Founder, Chairman and CEO, Dr. Robert E.W.

Key Points: 
  • The diagnostic test, developed under the direction of leading UBC microbiologist and the Company's Founder, Chairman and CEO, Dr. Robert E.W.
  • The diagnostic test builds off of a 2014 eBioMedicine paper6 that identified a sepsis gene expression signature among severely ill sepsis patients.
  • It should be noted that the Company's sepsis diagnostic technology is patented in China, Australia, and 13 European countries.
  • The Company has achieved significant milestones since its IPO on November 18, 2021, including —
    ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies

Retrieved on: 
Friday, December 23, 2022
Genome Canada, Organization, ASEP, Mortality, Death, United States Army, Patient, Overalls, Infection, Army of the United States, University, TM, CSE, Biofilm, Risk, Diagnosis, Probability, Disease, Inflammation, Sinusitis, Sepsis, News, Bill, FSE, Multimedia, Survival, Throat, Bill & Melinda Gates Foundation, Skin, Physician, Lung, Bacteria, Hospital, Vaccine, Pharmaceutical industry, Medical device, Medicine

Antibiotic failure is generally referred to as any situation where bacteria survive antibiotic treatment, and the clinical symptoms of the infection persist1.

Key Points: 
  • Antibiotic failure is generally referred to as any situation where bacteria survive antibiotic treatment, and the clinical symptoms of the infection persist1.
  • Asep Inc.'s diagnostic technology, SepsetER TM, is a blood-based gene expression assay that can provide an early and accurate diagnosis of severe incidences of the deadly disease sepsis.
  • SepsetER delivers results between 60-90 minutes whereas the conventional diagnostic tools may take approximately 8 - 36 hours.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/asep-medical-holdings-inc-achie...
    SOURCE ASEP Medical Holdings Inc.

Government of Canada launches consultations on the development of the Pan-Canadian Genomics Strategy

Retrieved on: 
Tuesday, May 24, 2022
Innovation, Science and Economic Development Canada, RNA transfection, DNA, Natural Resources, Social media, Climate change, Food, Environment, Government, Health, Review, Private sector, COVID-19, Research, Genome Canada, The Honourable, Genomics, Organization, Economic development, Adoption, Therapy, Government of Canada, Agriculture, Science, Industry

Today, the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry, announced the launch of public consultations for the upcoming Pan-Canadian Genomics Strategy.

Key Points: 
  • Today, the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry, announced the launch of public consultations for the upcoming Pan-Canadian Genomics Strategy.
  • The consultations will provide the government with valuable insights on the development of a strategy aimed to enhance federal investments in genomics and advance the commercialization and adoption of genomics to cement Canada's position as a leader in research and innovation.
  • "The Government of Canada recognizes that genomics is a key technology instrumental in responding to the national and global challenges of our time.
  • This is why our future Pan-Canadian Genomics Strategy will help cement Canada as a leader in genomics research and commercialize our genomics innovations and technologies, all while creating many important benefits for Canadians and positioning Canada for long-term success in the bioeconomy."